French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

ABC delivered the most reach for pharma, thanks to its coverage of the NBA playoffs and world news broadcasts.

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

His diet used to come in a juice box. Now, at 24, he’s learning how to eat, taste, and enjoy food for the first time — on ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...